| Texto completo | |
| Autor(es): |
Zuglianello, Carine
;
Franca, Angela P.
;
de Souza, Bruna S.
;
Agnes, Jonathan P.
;
Prediger, Rui D.
;
Lemos-Senna, Elenara
Número total de Autores: 6
|
| Tipo de documento: | Artigo Científico |
| Fonte: | International Journal of Biological Macromolecules; v. 281, p. 9-pg., 2024-10-11. |
| Resumo | |
Nasal delivery has emerged as a non-invasive route to administer drugs for brain delivery. In particular, poly- electrolyte complexes-based nanocarriers have been demonstrated to be advantageous for nasal delivery of peptide drugs and vaccines. Pramlintide (Pram) is a peptide that emerges as a novel neuroprotective strategy to modify the pathogenesis of Alzheimer's disease (AD). In this study, we examined the effects of the intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions (PEC-NE DexS/Pram ) in an experimental model of AD induced by intracerebroventricular (i.c.v.) infusion of amyloid-beta (A(31-42) 1-42 ) peptide in mice. PEC-NE DexS/Pram displayed droplet size lower than 200 nm and a negatively charged surface. The locomotor activity of the animals was not affected by the i.c.v. A(3 1-42 injection or Pram treatment. On the other hand, the intranasal administration of PEC-NE DexS/Pram at a dose of 100 mu g/day for 14 consecutive days restored the impairment induced by A(3 1-42 injection in the discriminative learning and the short-term spatial reference memory of mice. However, Pram treatment did not alter the A(3 1-42-induced anhedonic behavior, oxidative stress parameters, or the pre-synaptic SNAP-25 and post-synaptic PSD-95 levels in the hippocampus and prefrontal cortex. These findings indicate cognitive-enhancing properties of intranasal Pram administration in an animal model of AD. (AU) | |
| Processo FAPESP: | 14/50928-2 - INCT 2014: Nanotecnologia Farmacêutica: uma abordagem transdisciplinar |
| Beneficiário: | Maria Vitória Lopes Badra Bentley |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |